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Abstract 
Chronic diseases are often accompanied by inflammatory and degenerative processes. Estrogens 
have repeatedly been found to be involved in these processes. Testosterone (T) is the main pre-
cursor of estrogen in the brain and T replacement in chronic diseases has become important in 
recent years, prompting research on new T-conjugated molecules. We recently synthesized three 
new molecules including unsaturated fatty acid esters: T-linoleate (TL), T-oleate (TO) and T-eico- 
sapentanoate (TEPA). These substances were s.c. administered for 7 days to intact male rats sub-
jected to the formalin test (FT). Three other groups were included as comparisons: NAIVE, receiv-
ing no substance, OIL, treated with almond oil (vehicle), and TN, treated with T-undecanoate, a 
saturated fatty acid. Spontaneous behaviors and pain-induced responses were determined during 
the FT, hormones (T and dihydrotestosterone, DHT) were determined in blood, while estrogen 
receptors (ERα and β) were detected at the genomic and proteomic levels in the hippocampus, 
hypothalamus and spinal cord. In the hippocampus, ERα and ERβ mRNA levels were increased re-
spectively by TN and TL treatments with respect to OIL, whereas the hypothalamus TO and TL 
caused a decrease of ERα mRNA levels. At the proteomic level, TO, TL and TEPA decreased the lev-
els of ERα in the hypothalamus, whereas TEPA decreased ERβ in the spinal cord, hippocampus and 
hypothalamus. There was no effect of treatment on the spontaneous behaviors, while the TO and 
TL groups showed lower pain-induced behaviors (paw jerk frequency and licking duration) than 
the OIL group. TN increased paw jerk frequency and decreased licking duration with respect to 
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OIL. The treatments had no effect on T and DHT plasma levels. These results clearly indicate the 
possibility of pain and ER modulation by T-esters. 
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1. Introduction 
Testosterone (T) is increasingly recognized as a modulator of CNS processes and not only those related to re-
production. Adequate T serum levels are required in males and females for cellular growth, healing, mainte-
nance of muscle mass and bone, as well as CNS maintenance of opioid receptors, the blood-brain barrier and 
dopamine-norepinephrine activity [1]-[3]. Other important functions are involved in the occurrence and modula-
tion of pain. Indeed, numerous studies suggest that testosterone and its metabolites can influence pain processing 
[4]-[8] via both rapid and slow signals [9] [10]. Indirect proof of these actions is the fact that women suffer 
chronic painful syndromes more than men do [11] [12] and there are negative correlations between T levels and 
pain, i.e. lower pain in subjects with higher T levels [13]. We have reported beneficial effects of testosterone re-
placement therapy in chronic pain patients rendered hypogonadic by chronic assumption of opioids [14]. In ex-
perimental studies, testosterone was demonstrated to be analgesic in a variety of nociceptive tests [15] [16]. 
Moreover, a recent study in humans demonstrated the ability of T to modulate descending inhibitory pain path-
ways in women [17]. 
Testosterone is an androgen present in both sexes. It is considered a pro-hormone since most of its actions 
depend on the enzymes present in the cell: 5α-reductase reduces it to dihydrotestosterone (DHT) which acts like 
T on androgen receptors (AR); aromatase aromatizes it to estradiol (E2) which acts on estrogen receptors (ERα 
and ERβ) [6]. Both AR and ER are widely distributed throughout the CNS, e.g. spinal cord, hippocampus and 
hypothalamus targets for gonadal hormone actions involved in different aspects of pain modulation. In particular, 
the hippocampus is mostly involved in arousal, learning and memory and can play a significant role in pain 
modulation, as shown by different experimental approaches in both animal and human subjects [18]-[22]. ER 
are known to be involved in these functions; indeed ERα and ERβ have many enhancing effects on neuronal 
plasticity, behaviors related to cognition and mood [23] [24], and degenerative processes [25]. 
Due to aging or iatrogenic causes, testosterone levels may substantially decline and hypogonadic patients may 
experience symptoms of androgen deficiency including sexual dysfunction, dysphoric mood (anxiety, irritability 
and depression), lack of well-being, physical fatigue, changes in cognition, memory loss, insomnia, rheumatoid 
complaints, and pain [26]. Tajar et al. (2011) [27] reported that elevated levels of gonadotropins, but not sex 
steroids, are significantly associated with musculoskeletal pain in men. Recent studies also demonstrated a posi-
tive action of T on weight control in obese patients [28]. Testosterone compounds are usually based on T esteri-
fied with different molecules. One of the most commonly used long-term preparations is T esterified with the 
saturated fatty acid (FA) undecanoate to obtain testosterone undecanoate (TN). However, saturated FAs esteri-
fied with T could be hydrolyzed and follow metabolic pathways that might contribute to cardiovascular disease 
[29]. Therefore, we have explored the possibility of creating new substances in which T is esterified with un-
saturated fatty acids. These esters could also have beneficial effects on chronic disorders [30], including the 
prevention of hypercholesterolemia, atherosclerosis and inflammatory disease [31].  
Estrogen receptors are widely distributed in the brain. Their neuroprotective actions are summarized in a re-
cent review [25] in which the focus is on astrocytes in addition to the known effects on neurons. In astrocytes, 
estrogens are actively synthesized from testosterone via aromatase. This process can be greatly increased by in-
jury through enhancement of aromatase activity. We have shown strong modulation of aromatase by morphine 
in in vitro experiments on astrocytes [32]. 
The main goal of the present study was to investigate neural, behavioral and hormonal effects of supraphysi-
ological testosterone levels induced by s.c. injection into gonadally intact males rats of newly synthesized [33] T 
esters (testosterone-oleate: TO, testosterone-linoleate: TL, testosterone-eicosapentaenoic acid: TEPA) with re-
spect to the commercially available testosterone undecanoate (Testosterone Nebid®, TN), used as the reference 
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compound. We investigated the effects of the various T ester treatments on spontaneous and formalin-induced 
behaviors, testosterone and dihydrotestosterone (DHT) plasma levels, and ERα and ERβ levels in the hippo-
campus, hypothalamus and spinal cord. 
2. Materials and Methods  
2.1. Subjects 
Thirty-six male Wistar Han rats (Harlan-Nossan, Milan, Italy), weighing 200 - 225 grams at their arrival, were 
housed two per cage in plastic-bottomed cages with sawdust bedding. In each cage the animals were separated 
by a transparent Plexiglas wall with holes to allow partial social interactions. Cages were kept at room tempera-
ture 21˚C ± 1˚C, relative humidity 60% ± 10% and on a 12/12 h light/dark cycle (light off at 7 a.m.). Animals 
received food and water ad libitum.  
2.2. Experimental Procedures 
Experiments were carried out during the rats’ active period between 09:30 a.m. and 12:30 p.m. in a dedicated 
room under red light and white background noise. The experimental procedures were pre-approved by the ethics 
committee of the University of Siena and the National Institution for experiments in living animals. In all ex-
periments, attention was paid to the regulations for handling laboratory animals of the European Communities 
Council Directive (86/609/EEC) and the ethical guidelines for investigation of experimental pain in conscious 
animals issued by the ad hoc Committee of the International Association for the Study of Pain [34]. Particular 
efforts were made to minimize animal suffering and to reduce the number of animals used. 
One week after their arrival, the animals were randomly assigned to one of the experimental groups (n = 6 per 
group) according to the substance they would receive: T-undecanoate (TN, Nebid®, Bayer), T-oleate (TO), T- 
linoleate (TL), T-eicosapentaenoic acid (TEPA). All drugs were dissolved in sweet almond oil (OIL, vehicle, 
Laboratorio Farmaceutico Veneto FARVE, Italy) to obtain 1 mg/ml solutions to be administered to animals in a 
1 mg/Kg/die dosage according to the most recent determination of the animal’s body weight. The following 
groups were obtained: NAIVE (without any substance administration) and OIL, TN, TO, TL and TEPA (all s.c. 
injected with the relevant substance). 
All animals were treated from day 1 to day 7 (7 days). Treatment consisted in a subcutaneous (s.c.) injection 
of one of the substances on the back of the animal. Immediately after the injection, the rat was returned to its 
home cage. To evaluate possible changes in spontaneous and anxious behaviors after 5 days of treatment, all rats 
were subjected to the open field test (OF) for 30 min and to the elevated plus maze test for 5 min on day 5. On 
day 6, all rats were subjected to the formalin test to evaluate the effects of the treatment on the responses to a 
nociceptive stimulus: after receiving a s.c. injection of dilute formalin (50 μl, 5%) in the dorsal hind paw, they 
were placed in the open field apparatus and their behavior was recorded for 60 min. The day following the last 
s.c. treatment (day 8), the animals were anesthetized and perfused to allow tissue and blood collection.  
2.3. Open Field Test (Day 5)  
This test was carried out to study the treatment-induced effects on general behavior. Subjects were tested in an 
open field apparatus after 5 days of treatment. Both subjects of each home-cage were simultaneously transported 
to the experimental room (supplied with red light and white noise) and placed in identical open field apparatuses 
consisting of square Plexiglas cages (50 × 50 cm, 40 cm high). During the test (30 min), spontaneous behaviors 
were recorded and analyzed in six 5-min periods. The spontaneous behaviors considered were: rearing fre-
quency (number of times the animals stood on their fore limbs), self-grooming duration (time spent washing or 
scratching the face or body), locomotion duration (time spent sniffing and exploring the environment), sit alert 
duration (time spent motionless in an alert position), crouch (time spent motionless in a sleeping-like position); 
locomotor activity was also evaluated by counting the inner crossing (number of times the animal crossed the 
internal squares) and outer crossing (number of times the animal crossed the external squares).  
2.4. Elevated plus Maze (Day 5) 
The elevated plus maze apparatus consists of two open arms (50 × 10 cm) and two enclosed arms (50 × 10 × 40 
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cm high) opposite each other at 50 cm above the floor. At the beginning of the test, the rat was placed in the 
centre of the elevated plus maze and was then allowed to freely explore for 5 min. The testing room was quiet 
and lit with dim red light. The test was performed immediately after the OF test. The time the animal spent ex-
ploring the open arms was considered for the statistical analysis. 
2.5. Formalin Test (Day 6) 
For evaluation of the treatment-induced effects on persistent inflammatory pain, both subjects of a cage were 
simultaneously transported to the experimental room on day 6. They were gently restrained and s.c. injected 
with freshly prepared formalin solution (5% in 0.9% NaCl in a micro-syringe) on the dorsal surface of the right 
hind paw. After the injection, the rats were placed in the open field apparatus for 60 min. For assessment of the 
pain intensity and the behavioral effects of treatment, spontaneous and formalin-evoked behaviors were re-
corded for 60 min and analyzed in twelve 5-min periods. The analyzed behaviors were:  
1) Formalin-induced responses: licking duration (time spent licking the injected foot); flexing duration (time 
spent with the leg held off the floor, flexed close to the body); paw jerk frequency (number of phasic flexions of 
the leg).  
2) Spontaneous behaviors: the same behaviors analyzed in the open field test were considered, i.e. rearing 
frequency, self-grooming, locomotion, sit alert and crouch duration; locomotor activity (counting of inner 
crossing and outer crossing).  
2.6. Tissue Collection (Day 8) 
Twenty-four hours after the last treatment carried out on Day 7, the rats were anesthetized with sodium pento-
barbital (>100 mg/kg i.p.) and the abdomen was opened to collect blood. The animals were then intracardially 
perfused with phosphate buffered saline (PBS, about 300 ml) for exsanguination of the CNS. The spinal cord, 
hypothalamus and hippocampus were then collected. Tissues were divided into portions, immediately frozen in 
liquid nitrogen and stored at −80˚C for western blot analysis and RNA isolation.  
2.7. RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Total RNA from the hypothalamus, hippocampus and spinal cord was extracted and purified with the miRNeasy 
mini kit (Qiagen, Valencia, CA) following the manufacturer’s instructions. The RNA concentration was deter-
mined with a NanoDrop ND-100 spectrophotometer. qRT-PCR was performed to monitor the gene expression 
levels of ERα and ERβ. Five hundred nanograms of RNA were reverse transcribed with the iScript cDNA Syn-
thesis kit (Bio-Rad) for 5 min at 25˚C, 30 min at 42˚C and 5 min at 85˚C. One microliter of cDNA was ampli-
fied by RT-PCR using the Opticon II (Bio-Rad) and the SsoFast Eva-Green Master Mix (Bio-Rad) according to 
the manufacturer’s instructions. Forty PCR cycles were performed using an annealing temperature of 56˚C for 
ERα and 58˚C for ERß. Primers were specifically designed between two adjacent exons and synthesized by 
MWG. mRNA levels for each gene were normalized to those of Cyclofilin and the gene expression was ana-
lyzed using the ΔΔCt method. 
The primer sequences were: 
1) ERα  
Forward: AATTCTGACAATCGACGCCAG;  
Reverse: GTGCTTCAACATTCTCCCTCCTC. 
2) ERβ  
Forward: AAAGCCAAGAGAAACGGTGGGCAT; 
Reverse: GCCAATCATGTGCACCAGTTCCTT. 
3) Cyclofilin  
Forward: ACACGCCATAATGGCACTGG;  
Reverse: ATTTGCCATGGACAAGATGCC. 
2.8. Western Blot 
The hypothalamus, hippocampus and spinal cord tissue samples were homogenized (using a tissue homogenizer) 
in RIPA-B buffer (20 mmol/l sodium phosphate buffer, 150 mmol/l NaCl, 5 mmol/l EDTA, 1% Triton X-100, 
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and 0.5% sodium deoxycholate) supplemented with one tablet of cOmplete, Mini EDTA-free protease inhibitor 
cocktail (Roche Diagnostic, Mannheim, Germany) and sodium orthovanadate (1 mmol/l, pH 7.4). The homoge-
nates were clarified by centrifugation at 15,000 g for 15 min at 4˚C and prepared for immunoblot analysis. 
Total protein concentrations were determined via the Bio-Rad Dc protein assay protocol (Bio-Rad, Hercules, 
CA) followed by spectrophotometric analysis using the TECAN Genios plate reader and Magellan version 4.0 
software. Equal amounts of protein (50 μg) were loaded in each well, separated on SDS-PAGE gel (10% gradi-
ent gel; Bio-Rad, Hercules, CA) and transferred to nitrocellulose membranes (Millipore, Bedford, MA). The 
membranes were blocked with 3% milk and incubated overnight at 4˚C with a primary antibody ERα rabbit 
polyclonal antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA) and ERβ rabbit polyclonal antibody 
(1:500; Santa Cruz Biotechnology, Santa Cruz, CA). Primary antibody incubation was followed by incubation 
for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1:3000; Bio-Rad goat 
anti-rabbit). The blots were visualized in enhanced chemiluminescence solution (HRP chemiluminescence de-
tection kit, Bio-Rad) for 5 min and exposed to X-ray film (Thermo scientific, Pierce Biotechnology, Rockford, 
IL, USA) for 5 - 20 min. Equal loading of the proteins was confirmed by staining the blots with a 10% (v/v) 
Ponceau S solution (2% Ponceau S in 30% trichloroacetic acid/30% sulfosalicylic acid, Sigma Chemical Co). 
The ratio of the densitometric values obtained in the estrogenic-specific chemiluminescence reaction and the 
major Ponceau S-stained membrane bands (loading control) was calculated. The western blot analysis was per-
formed in triplicate. The band density was measured with a computer-assisted imaging analysis program (Quan-
tity One Software, Bio-Rad, Milan, Italy) and normalized against the corresponding loading control.  
2.9. Hormone Determinations 
Blood samples were collected from the abdominal vein in EDTA-added syringes. Blood was centrifuged (3000 
g for 10 min at 4˚C) to obtain plasma and the samples were then frozen at −20˚C until the assay. The ADVIA 
Centaur assay, a competitive immunoassay using direct chemiluminescent technology, was used to measure tes-
tosterone (T) and dihydrotestosterone (DHT) plasma levels. The intra-assay and inter-assay coefficients of 
variation were 5% and 8% respectively for all determinations.  
2.10. Statistical Analysis  
The pain response data were processed by analysis of variance (ANOVA) with the factors Treatment (five levels: 
OIL, TN, TO, TL, TEPA) and Time (twelve 5-min intervals), whereas spontaneous behaviors recorded during 
the formalin and open field tests were analyzed as total values of each behavior with the factor Treatment (five 
levels: OIL, TN, TO, TL, TEPA). The elevated plus maze, hormone, western blot and RT-PCR data were proc-
essed by one-way ANOVA with the factor Treatment (five levels: OIL, TN, TO, TL, TEPA), followed by the 
post-hoc Bonferroni test. GraphPad Prism Version 4.0 (GraphPad Software, Inc., San Diego, CA) was used and 
the significance level was set at (*)p < 0.05.  
3. Results 
The weight and general physical condition of each rat were checked during the experimental phases. No abnor-
mal weight changes or signs of physical impairment were observed.  
3.1. Effects of Treatments on Estrogen Receptor (ERα and ERβ) mRNA Levels 
mRNA levels of ERα and ERβ were determined by quantitative RT-PCR in the hypothalamus and hippocampus 
samples. In Figure 1, the data are represented as fold change with respect to the NAIVE level (gene expression 
= 1). 
For ERα gene expression in the hippocampus (Figure 1(A)), the significant effect of Treatment (F4,19 = 2.244, 
p = 0.0002) was due to differences among groups: TN showed higher levels than OIL (p < 0.01), TO (p < 0.05) 
and TL (p < 0.001); moreover, TEPA had a higher level than TL (p < 0.05). In the hypothalamus (Figure 1(B)), 
the significant effect of Treatment (F4,29 = 6.300, p = 0.0012) was due to the lower levels in TO and TL than in 
OIL (p < 0.01 for both).  
For ERβ gene expression in the hippocampus (Figure 1(C)), TL had higher levels than OIL (p < 0.05) 
(Treatment: F4,29 = 3.421, p = 0.0231). No significant effect of treatment was found for the hypothalamus (F4,29 = 
2.2431, p = 0.0931) (Figure 1(D)).  
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Figure 1. RT-PCR analysis. Quantification of ERα ((A) and (B)) and ERβ ((C) and (D)) 
mRNA levels in the hypothalamus ((B) and (D)) and hippocampus ((A) and (C)) of treated 
animals (OIL, TN, TP, TO, TL and TEPA). Data are shown as mean ± SEM of fold changes 
with respect to the NAIVE group (not shown). *p < 0.05 and **p < 0.001, vs OIL; #p < 0.05 
and ##p < 0.001, vs TN; §p < 0.05, vs TL.                                                
3.2. Effects of Treatments on CNS ERα and ERβ Levels  
We performed western blot analysis to demonstrate treatment effects on ERα and ERβ proteins in the hypo-
thalamus, hippocampus and spinal cord. In the hypothalamus and hippocampus, ERα expression was detected as 
a full-length ERα band at 66 kDa and another immunoreactive band at 52 KDa, as already reported [35]. No de-
tectable ERα protein levels were found in the spinal cord.  
One-way ANOVA showed no significant effect of Treatment on ERα levels in the hippocampus (F4,12 = 1.441, 
p = 0.3053, Figure 2(A)) or in the hypothalamus (F4,13 = 3.316, p = 0.0625, Figure 2(B)). 
In the same CNS regions, ERβ protein expression was detected as a single band at 55 kDa.  
There was a significant effect of Treatment on ERβ levels in the spinal cord (F4,16 = 3.466, p = 0.0421, Figure 
3(A)) due to the lower levels in TEPA-treated animals than in OIL-treated ones (p < 0.05). In the hippocampus 
(Figure 3(B)), there was a significant effect of Treatment (F4,14 = 3.538, p = 0.0478), which tended to be lower 
in animals treated with TL and TEPA. The significant effect of Treatment (F4,9 = 5.366, p = 0.047) in the hypo-
thalamus (Figure 3(C)) was due to the lower levels in TO, TL and TEPA than in OIL (p<0.05 for all).  
3.3. Behavioral Data 
3.3.1. Open Field (30 min) 
One-way ANOVA was applied to the total spontaneous behaviors recorded during the open field test with the 
factor Treatment (five levels: OIL, TN, TO, TL, TEPA, see Table 1). There was a significant effect of Treat-
ment on grooming duration (F5,30 = 3.232, p = 0.02), since TO showed a higher value than OIL (p < 0.01), TN (p 
< 0.01) and TL (p < 0.01). Crouch duration was significantly different among groups (F5,30 = 2.804, p = 0.034): 
TO was higher than OIL and TEPA (p < 0.01 and p < 0.04, respectively) and TL was higher than OIL (p < 0.01). 
Sit alert and locomotion duration and rearing frequency were not affected by the treatment. 
Locomotor activity was also evaluated by counting of internal and external crossing. However, Treatment had 
a significant effect only on internal crossing (F5,30 = 2.73, p = 0.038): TL showed lower internal crossing than 
OIL and TN (p < 0.004, p < 0.05, respectively) while TEPA was lower than OIL (p < 0.03). 
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Figure 2. Western blot analysis and identification of ERα protein in rat CNS tissues. (Left) Data 
(mean ± SEM) are expressed as fold change with respect to NAIVE. (Right) Ponceau staining 
shows equal protein loading. *p < 0.05 OIL.                                                       
 
   
Figure 3. Western blot analysis and identification of ERβ protein in CNS tissues. (Left) Data (mean ± SEM) are expressed as 
fold increase with respect to NAIVE. (Right) Representative western blot analysis of ERβ in the spinal cord (A), hippocam-
pus (B) and hypothalamus (C) of treated animals (OIL, TN, TO, TL, TEPA). *p < 0.05 OIL, §p < 0.05 vs TEPA.                      
 
Table 1. Table of total spontaneous behaviors determined during the open field test (30 min) in animals belonging to 
the five treated groups (OIL, TN, TO, TL, TEPA). Data represent the mean ± SEM of the total time or frequency of 
each behavior. *vs TO, p < 0.01 for all; #vs OIL, p < 0.03; §vs TL, p < 0.01.                                            
Behaviors OIL TN TO TL TEPA 
Internal Crossing (n) 102.3 ± 19.4§ 80.2 ± 12.5§ 62.8 ± 5.7 41.8 ± 54.5 58.0 ± 7.4§ 
External Crossing (n) 349.7 ± 35.6 232.8 ± 41.1 356.7 ± 36.1 296.8 ± 54.5 340.5 ± 20.3 
Locomotion (sec) 1294.5 ± 113.1 1223.0 ± 101.1 975.3 ± 65.9 1106.2 ± 143.3 1151.5 ± 122.7 
Sit Alert (sec) 237.0 ± 84.9 156.2 ± 70.5 109.7 ± 25.0 167.7 ± 64.2 206.0 ± 53.0 
Grooming (sec) 207.5 ± 43.7* 207.2 ± 39.3* 361.2 ± 49.5 198.8 ± 27.5* 297.7 ± 55.0 
Rearing (sec) 130.8 ± 20.9 91.8 ± 16.7 79.5 ± 11.7 86.5 ± 15.8 104.0 ± 7.2 
Crouch (sec) 61.0 ± 25.0* 213.7 ± 74.6 355.8 ± 93.8 328.3 ± 89.1# 144.8 ± 28.3* 
3.3.2. Elevated plus Maze 
One-way ANOVA applied to the time spent by animals exploring the open arms did not reveal any significant 
difference among groups. 
3.3.3. Formalin Test 
1) Pain-induced responses 
Formalin-induced responses were analyzed by repeated measure ANOVA applied to each pain response 
(licking, flexing and jerking of the injected paw) with the factors Treatment (five levels: OIL, TN, TO, TL, 
TEPA) and Time (twelve 5-min intervals). 
2) Paw jerk 
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There was a strong tendency towards a significant Treatment × Time interaction (F44,275 = 1.3914, p = 0.060). 
Post-hoc analysis revealed some significances that need to be underlined in light of the neural response. In par-
ticular, TO had lower levels than OIL at 20 and 50 min (p < 0.01 and p < 0.03, respectively), while TN was 
higher than OIL from 35 to 45 min (p < 0.04 and p < 0.01, respectively) (Figure 4(A)).  
3) Licking 
Licking duration was only affected by Treatment in the first phase (0 - 5 min) (F4,25 = 32.98, p = 0.038) due to 
higher levels in OIL than in TN (p < 0.01), TO (p < 0.04) and TL (p < 0.004). No significant differences among 
groups were found in the second phase (Figure 4(B)). 
4) Flexing 
Repeated measure ANOVA did not reveal any significant differences among groups in flexing duration 
(Figure 4(C)). 
 
 
 
 
Figure 4. Formalin test (FT): histograms of total frequency or duration of each 
pain induced response during the first and the second phase of the FT in all the 
treated groups (OIL, TN, TO, TL, TEPA). Each insert represents the time course 
of the pain responses in the 60 min of the FT, divided into twelve 5-min periods. 
(A) Paw jerk frequency; (B) Licking duration; (C) Flexing duration. Data repre- 
sent mean ± SEM. *p < 0.01 vs OIL.                                          
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3.4. Hormone Plasma Levels  
The effects of treatments on testosterone and dihydrotestosterone plasma levels were examined at the end of the 
experiment. One-way ANOVA did not reveal any significant differences among groups (Figure 5). 
4. Discussion  
The main result of the present study is that ER RNA expression and protein levels are sensitive to treatment with 
testosterone esters, albeit differently in the two ER types. The T esters used in the present study were obtained 
[33] by combining the T molecule with unsaturated fatty acids presenting different degrees of unsaturation and 
belonging to the predominant fatty acid families: oleic, linoleic and eicosapentaenoic (EPA) acids. These com-
pounds (T-oleic, T-linoleic and T-EPA) were found to be stable and not toxic in fibroblasts and astrocytes [33]. 
Thus it was possible to perform in vivo studies in intact male rats. In these subjects, spontaneous behaviors and 
testosterone and DHT plasma levels were not significantly affected by treatments, suggesting that all compounds 
were metabolized without apparent interference with the nervous and endocrine systems. However, important 
changes were observed in brain ER RNA expression and protein levels, suggesting possible long-term effects on 
cognitive functions.  
Estrogens are known to modulate attention, learning and memory but also to have neuroprotective actions 
able to counteract inflammation or other brain injuries. Moreover, there is a strong suggestion that estrogen 
plays a key role in pain occurrence and modulation via both ERα and ERβ receptors. Since testosterone is the 
main source of estrogens in the brain (neurons and astrocytes have P450Arom to transform T into estradiol), 
understanding how circulating testosterone can regulate the expression of estrogen receptors is important. In-
deed a change in the availability of ERα and ERβ proteins in sensory neurons could influence their sensitivity to 
estrogen. In the present study, we examined the levels of ER protein and mRNA in the hypothalamus, hippo-
campus and spinal cord using the regulation of both ER isoforms as a parameter for estrogen responsiveness (in 
this case to locally produced estrogens) and to investigate their modulation after hormonal manipulation.  
Each treatment had a strong and independent affect on the transcription and expression of both estrogen re-
ceptors. While TN increased ERα in the hippocampus, TL not only blocked this increase but tended to decrease 
ERα in this brain area. Interestingly ERβ showed a completely different effect since the higher levels were in the 
TL group. In the hypothalamus, ERα were decreased in the TO and TL groups, while ERβ did not change. 
Similar changes were observed in the ER protein levels.  
The use of entire tissue could mask T-induced changes in gene and protein expression that are neuron-specific, 
e.g. T might differentially regulate gene and protein expression depending on the neuron/cell type. Nevertheless, 
the results are highly consistent, indicating that the different FA attached to the T molecule could differently af-
fect its interaction with cells. Interestingly, a high transcriptional level does not translate into an increased ex-
pression of protein, and vice versa. Although the protein expression patterns often match the mRNA expression 
patterns, there are examples in which ER protein levels are not correlated with ER mRNA expression [36] [37].  
Estrogens exert their effects through genomic and non-genomic mechanisms [38] [39]; indeed their activation 
alters the expression of certain genes and neurotransmitters in sensory neurons [40] [41]. Recently it was shown 
that activation of astrocytes after injury or inflammation results in increased expression of ER and de novo ex- 
 
    
Figure 5. (A) Testosterone and (B) dihydrotestosterone (DHT) plasma levels determined in all 
treated groups (OIL TN, TP, TL AND TEPA) at the end of the formalin test. Each bar represents the 
mean ± SEM.                                                                         
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pression of aromatase [25]. In the spinal cord, ERα were found to mediate the pro-nociceptive effect of estradiol 
on visceral signal processing through activation of the MAPK pathway [42]. Furthermore, ERβ knockout mice 
showed lower nociceptive responses than wild type mice [43]. These findings are particularly interesting in the 
light of these preliminary results suggesting that substances modulating ERα and ERβ can positively modulate 
pain or inflammation in general.  
It has been shown that ER expression is regulated by estrogens in the brain [44]-[46] as an auto-regulatory 
feedback loop [47]. Moreover, Patisaul et al. (1999) [48] demonstrated that ERα and ERβ mRNA expression is 
down-regulated by estrogen in a region-specific manner in the rat brain. The molecular mechanisms underlying 
the regulation of ER expression by testosterone have not been elucidated. However, since aromatase is the key 
enzyme for synthesis of estrogens from androgens and is responsible for controlling the androgen/estrogens ratio, 
it is possible that the down-regulation of ER protein present in some of our treatment groups might be due to in-
creased local estrogen biosynthesis resulting from the circulating testosterone. In hippocampal neurons, aroma-
tase-mediated estrogen production appears to be involved in an auto/paracrine feedback mechanism to regulate 
ERα and ERβ expression [49]. It is likely that estrogens induce proteasome-mediated proteolysis of ERα and 
ERβ, a system responsible for degradation of most proteins in mammalian cells. This swift estrogen-dependent 
protein degradation could account for a rapid decline of ER protein by testosterone treatment without changes in 
the levels of ER mRNA. Alternatively, the testosterone may act post-transcriptionally to down-regulate ERα and 
ERβ protein levels. The mechanism for this is not currently known. Nonetheless, it is possible that testosterone 
activates proteolysis by inducing the expression of kinases that activate the ubiquitin proteasome pathway.  
While the molecular actions of steroid hormones mediated by their receptors have been extensively studied in 
the brain and in peripheral tissues, considerably less is known about the molecular mechanisms that regulate the 
expression of the steroid hormone receptors themselves. However, the mechanisms underlying ER regulation by 
testosterone may involve different transcriptional and/or post-transcriptional events which will likely be cell and 
tissue specific as well as gender specific. Polyunsaturated fatty acids (PUFAs) are well known and widely util-
ized because of the variety of their biological effects, particularly those related to the cardiovascular system. 
Based on recent evidence we have hypothesized that the demonstrated analgesic action of testosterone [50] 
would be strengthened by supplementation of the testosterone with (n − 3) PUFAs, since n − 3 FAs can modu-
late inflammatory metabolic pathways [51]. We used the formalin test because it allows quantification of pain 
intensity without any external interference. Once injected in the paw, the irritant induces pain responses that can 
be easily measured. Thus, this model can be used to evaluate modulation of the inflammatory condition by tes-
tosterone treatment. The formalin-induced responses revealed different analgesic effects of the treatments de-
pending on the T-esters used: TO and TL were analgesic in terms of both paw jerk and licking, while no de-
crease in these responses was present in the TN group.  
Therefore, these new esters involving important unsaturated FAs could play a role in the treatment of chronic 
pain, owing to not only their anti-inflammatory effect but also their ability to improve the stability and pharma-
cokinetics of testosterone. For this reason, the combination of an n − 3 PUFA with testosterone could represent 
an interesting approach in hormone replacement therapy. 
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